Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082381 · ClinicalTrials.gov registry record · Phase 3
Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 551
- Enrollment target
NCT00082381 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 551 participants.
The verdict
NCT00082381, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 551 participants
- Enrollment target
Study Summary
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
Interventions
- DRUG Insulin glargine
- DRUG Exenatide (AC2993)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 551 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082381
The ClinicalTrials.gov registry entry for NCT00082381 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 551 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine is the first listed.
NCT00082381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082381 about?
NCT00082381 is a clinical study titled "Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin". This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
What is the current status of trial NCT00082381?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 551 participants. The study started on 2003-06. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00082381?
The interventions under investigation include: Insulin glargine (DRUG), Exenatide (AC2993) (DRUG).
Who is sponsoring clinical trial NCT00082381?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.